Jetema Co., Ltd. (216080) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jetema Co., Ltd. (216080:KRX), powered by AI.

Current Price
₩4,970
P/E Ratio
-28.1
Market Cap
185.3B
Sector
Healthcare
What is the Jetema Co., Ltd. stock price forecast?

Jetema Co., Ltd. is currently trading at ₩4,970. View real-time AI analysis on Alpha Lenz.

What is Jetema Co., Ltd. insider trading activity?

View the latest insider trading data for Jetema Co., Ltd. on Alpha Lenz.

What is Jetema Co., Ltd.'s P/E ratio?

Jetema Co., Ltd.'s P/E ratio is -28.1.

Jetema Co., Ltd.

KRX · 216080
₩4,970+115(+2.37%)Market closedKRX regular session 09:00–15:30 KST
Ask about Jetema Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Jetema Co., Ltd. trades at a P/E of -28.1 (undervalued) with modest ROE of -9.6%. 3Y revenue CAGR of 18.7% highlights clear growth momentum.

Ask for details

Company Overview

Jetema Co., Ltd., a South Korean company, is primarily engaged in the biotechnology sector, focusing on developing, manufacturing, and marketing medical aesthetics and pharmaceuticals. The firm's core products include botulinum toxin, commonly used in non-surgical cosmetic procedures, and hyaluronic acid fillers, designed for skin rejuvenation and anti-aging treatments. Jetema Co., Ltd. also engages in the production of microneedles aimed at drug delivery applications, showcasing its commitment to innovative medical technologies. The company serves a variety of markets, impacting not only the beauty and cosmetics industry but also the pharmaceutical sector through its research-driven approach. By leveraging advanced biotechnology, Jetema Co., Ltd. aims to provide effective solutions for both aesthetic enhancements and therapeutic treatments. In the financial market, Jetema Co., Ltd. represents an entity focused on combining scientific research with consumer demand for beauty and health products. It plays a significant role in the cosmetic procedures market, which is experiencing growth due to increasing consumer interest in anti-aging solutions and non-invasive medical treatments globally.

CEO김재영, 남정선 (각자대표)
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees235

Company Statistics

FY 2025

Profile

₩185,316,882,030Market Cap
₩76,902,884,060Revenue
37.29MShares Out
235Employees

Margins

47.90%Gross
10.99%EBITDA
4.97%Operating
-10.00%Pre-Tax
-9.68%Net

Valuation

-28.07P/E
2.83P/B
2.41EV/Sales
35.14EV/EBITDA
-38.61P/FCF

Growth (CAGR)

18.69%Rev 3Yr
30.07%Rev 5Yr
-1.58%Op Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.45%ROA
-9.59%ROE
1.34%ROIC

Financial Health

₩4,888,614,000Cash & Cash Equivalents
₩139,245,072,340Net Debt
221.74%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Jetema Co., Ltd. (ticker: 216080) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). It has approximately 235 employees. Market cap is $185.3B.

The current price is ₩4,970 with a P/E ratio of -28.07x and P/B of 2.83x.

ROE is -9.59% and operating margin is 4.97%. Annual revenue is $76.9B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Jetema Co., Ltd. (216080) Stock Forecast 2026 ₩4,970 — Price, Financials & Analyst Targets | Alpha Lenz